Magprol CR 500 Tablet contains Magnesium Valproate 500 mg as its active ingredient and is primarily indicated for the management of epilepsy and bipolar disorder. Magnesium Valproate acts as an anticonvulsant and mood stabilizer by modulating the activity of gamma-aminobutyric acid (GABA) in the central nervous system, thereby reducing neuronal excitability and preventing seizure activity. This controlled-release formulation ensures a sustained plasma concentration, improving therapeutic efficacy and patient compliance by allowing once or twice-daily dosing. Magprol CR 500 is effective in treating various types of seizures, including generalized tonic-clonic, absence, and partial seizures, as well as in stabilizing mood fluctuations in bipolar affective disorder. It should be used under medical supervision, with dosage individualized based on clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, dizziness, weight gain, and tremors, while serious side effects such as hepatotoxicity and pancreatitis, although rare, require immediate medical attention. Regular monitoring of liver function tests and blood counts is recommended during prolonged therapy. Magprol CR 500 should be used cautiously in patients with hepatic impairment, and abrupt discontinuation should be avoided to prevent seizure recurrence.